Cartesian receives FDA RMAT designation for Descartes-08 for treatment of MG

Cartesian Therapeutics announced that the U.S. Food and Drug Administration, FDA, has granted Regenerative Medicine Advanced Therapy, RMAT, designation for Descartes-08 for the treatment of myasthenia gravis, MG. Descartes-08, the Company’s lead product candidate, is an autologous mRNA CAR-T directed against the B cell maturation antigen initially being developed for the treatment of MG. “Receipt of RMAT designation underscores our belief that Descartes-08, our potential first-in-class mRNA CAR-T cell therapy, could serve as a meaningful addition to the MG treatment landscape,” said Carsten Brunn, Ph.D., President and Chief Executive Officer of Cartesian. “We look forward to working closely with the FDA to efficiently advance the development of Descartes-08 for this underserved population. Looking ahead, we remain on track to report topline data from our ongoing Phase 2b study in patients with MG in the middle of this year.”